{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:07:09Z","timestamp":1792602429704,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009590","name":"Gansu Education Department","doi-asserted-by":"publisher","award":["2022CYZC-04"],"award-info":[{"award-number":["2022CYZC-04"]}],"id":[{"id":"10.13039\/501100009590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022817","name":"Lanzhou University Second Hospital","doi-asserted-by":"publisher","award":["CY2021-MS-A11"],"award-info":[{"award-number":["CY2021-MS-A11"]}],"id":[{"id":"10.13039\/100022817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.intimp.2025.115057","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:34:32Z","timestamp":1750430072000},"page":"115057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer"],"prefix":"10.1016","volume":"162","author":[{"given":"Wei","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualan","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panfeng","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2025.115057_bb0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder Cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115057_bb0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against Intravesical BCG for high-risk high-grade nonmuscle invasive bladder Cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115057_bb0015","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN guidelines\u00ae insights: bladder Cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.intimp.2025.115057_bb0020","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"6(6):CD009294","author":"Han","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2025.115057_bb0025","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage ta T1 bladder Cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115057_bb0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events with Nivolumab Efficacy in non\u2013small-cell lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"issue":"22","key":"10.1016\/j.intimp.2025.115057_bb0035","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","article-title":"Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal Cancer","volume":"23","author":"Scurr","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2025.115057_bb0040","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"issue":"15","key":"10.1016\/j.intimp.2025.115057_bb0045","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1158\/0008-5472.CAN-22-3382","article-title":"PP2Ac deficiency enhances tumor immunogenicity by activating STING\u2013type I interferon signaling in glioblastoma","volume":"83","author":"Mondal","year":"2023","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.115057_bb0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.15698\/cst2021.04.247","article-title":"Inhibitory DAMPs in immunogenic cell death and its clinical implications","volume":"5","author":"Hayashi","year":"2021","journal-title":"Cell Stress"},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0055","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4049\/jimmunol.1900930","article-title":"Tumor microenvironment following gemcitabine treatment favors differentiation of immunosuppressive Ly6Chigh myeloid cells","volume":"204","author":"Wu","year":"2020","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115057_bb0060","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/2326-6066.CIR-17-0229","article-title":"Natural killer T-cell immunotherapy in combination with chemotherapy-induced immunogenic cell death targets metastatic breast Cancer","volume":"5","author":"Gebremeskel","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0065","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1038\/s41467-020-19970-9","article-title":"Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death","volume":"11","author":"Hayashi","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2025.115057_bb0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential Intravesical gemcitabine and docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder Cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.intimp.2025.115057_bb0075","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115057_bb0080","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1245\/s10434-011-1609-3","article-title":"Association of Intra-tumoral Infiltrating Macrophages and Regulatory T Cells is an independent prognostic factor in gastric Cancer after radical resection","volume":"18","author":"Wang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in Cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115057_bb0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrm3735","article-title":"Self-consumption: the interplay of autophagy and apoptosis","volume":"15","author":"Mari\u00f1o","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115057_bb0095","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","article-title":"Decisions about dendritic cells: past, present, and future","volume":"30","author":"Steinman","year":"2012","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115057_bb0110","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.drudis.2014.02.008","article-title":"Dendritic cell-based cancer immunotherapy: the stagnant approach and a theoretical solution","volume":"19","author":"Subbotin","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.0105-2896.2010.00896.x","article-title":"Perforin: structure, function, and role in human immunopathology","volume":"235","author":"Voskoboinik","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2025.115057_bb0120","doi-asserted-by":"crossref","first-page":"1392535","DOI":"10.3389\/fimmu.2024.1392535","article-title":"Reassessing granzyme B: unveiling perforin-independent versatility in immune responses and therapeutic potentials","volume":"15","author":"Thompson","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115057_bb0125","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1386829","article-title":"Trial watch: immunogenic cell death induction by anticancer chemotherapeutics","volume":"6","author":"Garg","year":"2017","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.intimp.2025.115057_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23327","article-title":"Chemoimmunotherapy with doxorubicin and caffeine combination enhanced ICD induction and T-cell infiltration in B16F10 melanoma tumors","volume":"37","author":"Yerragopu","year":"2023","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.intimp.2025.115057_bb0135","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jconrel.2022.06.039","article-title":"Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression","volume":"348","author":"Kim","year":"2022","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.intimp.2025.115057_bb0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","article-title":"Endoplasmic reticulum stress signals in the tumour and its microenvironment","volume":"21","author":"Chen","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin\u2013driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2025.115057_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102351","article-title":"Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma","volume":"54","author":"Xu","year":"2022","journal-title":"Redox Biol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115057_bb0155","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.3390\/cancers13112821","article-title":"Restoring the immunity in the tumor microenvironment: insights into immunogenic cell death in Onco-therapies","volume":"13","author":"Hern\u00e1ndez","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0160","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41420-025-02376-1","article-title":"Cell death in tumor microenvironment: an insight for exploiting novel therapeutic approaches","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.intimp.2025.115057_bb0165","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nri.2017.9","article-title":"Dying cells actively regulate adaptive immune responses","volume":"17","author":"Yatim","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115057_bb0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115057_bb0175","series-title":"Cancer Immunosurveillance. Vol 1884. Methods in Molecular Biology","first-page":"297","article-title":"Gold standard assessment of immunogenic cell death in oncological mouse models","author":"Humeau","year":"2019"},{"issue":"575","key":"10.1016\/j.intimp.2025.115057_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6110","article-title":"Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer","volume":"13","author":"Oresta","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.intimp.2025.115057_bb0185","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/emboj.2009.1","article-title":"Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death","volume":"28","author":"Panaretakis","year":"2009","journal-title":"EMBO J."},{"issue":"31","key":"10.1016\/j.intimp.2025.115057_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202309583","article-title":"Multiple treatment of triple-negative breast Cancer through Gambogic acid-loaded mesoporous Polydopamine","volume":"20","author":"Liu","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.intimp.2025.115057_bb0195","doi-asserted-by":"crossref","DOI":"10.1172\/JCI32567","article-title":"TNF-\u03b1 is critical for antitumor but not antiviral T cell immunity in mice","author":"Calzascia","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.intimp.2025.115057_bb0200","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.coph.2004.04.004","article-title":"Tumor necrosis factor-\u03b1 in the pathogenesis and treatment of cancer","volume":"4","author":"Anderson","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115057_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.621931","article-title":"Interleukin-1 as innate mediator of T cell immunity","volume":"11","author":"Van Den Eeckhout","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115057_bb0210","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/0008-5472.CAN-09-3566","article-title":"Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity","volume":"70","author":"Aymeric","year":"2010","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2025.115057_bb0215","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1\u03b2\u2013dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115057_bb0220","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.18632\/oncotarget.2948","article-title":"Inhibition of HIF-1\u03b1 by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2025.115057_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2016.12.011","article-title":"Gemcitabine: selective cytotoxicity, induction of inflammation and effects on urothelial function","volume":"316","author":"Farr","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115057_bb0230","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.intimp.2025.115057_bb0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cyto.2017.05.024","article-title":"Cytokines in immunogenic cell death: applications for cancer immunotherapy","volume":"97","author":"Showalter","year":"2017","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.intimp.2025.115057_bb0240","doi-asserted-by":"crossref","first-page":"e00207","DOI":"10.1128\/JVI.00207-19","article-title":"By binding CD80 and CD86, the vaccinia virus M2 protein blocks their interactions with both CD28 and CTLA4 and potentiates CD80 binding to PD-L1. Shisler JL, ed","volume":"93","author":"Kleinpeter","year":"2019","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0245","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/cdd.2013.75","article-title":"Molecular mechanisms of ATP secretion during immunogenic cell death","volume":"21","author":"Martins","year":"2014","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.intimp.2025.115057_bb0250","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115057_bb0255","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.oraloncology.2019.06.016","article-title":"Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer","volume":"95","author":"Park","year":"2019","journal-title":"Oral Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115057_bb0260","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0265","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115057_bb0275","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","article-title":"Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer","volume":"58","author":"Davis","year":"2016","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0280","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast Cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"issue":"7\u20138","key":"10.1016\/j.intimp.2025.115057_bb0285","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.intimp.2009.03.015","article-title":"Gemcitabine directly inhibits myeloid derived suppressor cells in BALB\/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice","volume":"9","author":"Le","year":"2009","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115057_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101202","article-title":"Macrophage polarization synergizes with oxaliplatin in lung cancer immunotherapy via enhanced tumor cell phagocytosis","volume":"14","author":"Li","year":"2021","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0295","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10555-011-9273-4","article-title":"Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy","volume":"30","author":"Kepp","year":"2011","journal-title":"Cancer Metastasis Rev."},{"issue":"7","key":"10.1016\/j.intimp.2025.115057_bb0300","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1083\/jcb.201110131","article-title":"The impact of the unfolded protein response on human disease","volume":"197","author":"Wang","year":"2012","journal-title":"J. Cell Biol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115057_bb0305","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, regulation and functions of the unfolded protein response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115057_bb0310","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1196\/annals.1299.032","article-title":"Caspase-12 and ER-stress-mediated apoptosis: the story so far","volume":"1010","author":"Szegezdi","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925010471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925010471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:29:52Z","timestamp":1786159792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925010471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":62,"alternative-id":["S1567576925010471"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115057","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115057"}}